Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Catalyst Biosciences Inc (CBIO) today and set a price target of $35. The company’s shares closed yesterday at $8.29, close to its 52-week low of $8.14.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 13.6% and a 42.8% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Catalyst Biosciences Inc with a $35 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $37 and a one-year low of $8.14. Currently, Catalyst Biosciences Inc has an average volume of 180.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant.
